Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will participate in two upcoming investor conferences.

President and Chief Executive Officer, Dan Browne, is scheduled to present at the William Blair 38^th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 12 at 1:30pm CT.

President and Chief Executive Officer, Dan Browne, is also scheduled to participate in a fireside chat discussion at the Goldman Sachs 39^th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 13 at 10:00am PT.

Interested parties can access the live audio webcasts for both conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 30 days.

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180605005089/en/